Table 3.

Strength of Recommendations and Evidence (When Available) Related to 7 Antipsychotic Measure Concepts

Guideline*	Strength of Recommendation and Evidence Ratings‡ by Antipsychotic Measure Concept
	Use in Very Young Children	Multiple Concurrent Antipsychotics	Higher Than Recommended Doses	Use Without a Primary Indication	Access to Psychosocial Interventions	Metabolic Screening	Follow-up Visit With Prescriber
AACAP-AAA	Strong	Strong	Moderate	Strong	Strong	Strong	Strong
AACAP-PsyMed		Unrated					Unrated
AACAP-BP					Strong	Strong	Strong
AACAP-ODD				Moderate	Strong
AACAP-SZ			Strong		Strong	Strong	Strong
CAMESA†						Strong (SOR)‡, high (SOE)‡
PPWG§	Strong–weak†			Strong–weak†	Strong–weak†	Unrated	Unrated
TRAAY			Unrated	Unrated	Unrated	Unrated
T-MAY		Strong (SOR), weak (SOE)	Unrated	Unrated	Strong (SOR), high (SOE)	Strong (SOR), high (SOE)
TX	Unrated	Unrated	Unrated	Unrated		Unrated	Unrated
APA-CW				Unrated
Totals
CPG with recommendation	3	4	5	7	7	8	6
CPG with rated recommendation	2	2	2	3	6	5	3
CPGs with	2	2	1	2	6	5	3
SOR = strong
CPGs with	0	0	0	0	1	2	0
SOE = strong

CPG indicates clinical practice guidelines; SOR, strength of recommendation; and SOE, strength of evidence.

^*See Table 1 for full names.

^†CAMESA provides ratings of both SOR and SOE and rate each antipsychotic medication, each time interval (0, 3, 6, 12 months) and each test separately. All combinations cannot be shown, but in general, testing is strongly recommended, and evidence is rated highest at 0 and 3 months.

^‡CPG ratings were categorized as strong/high, moderate, or weak to facilitate comparisons across guidelines (see Table 2). Most guideline rating systems did not rate strength of recommendation and evidence separately. To be conservative, we consider all ratings as SOR unless it is specified that the rating is for SOE.

^§PPWG provides ratings for each step of treatment algorithms for 9 different diagnoses. All combinations cannot be represented; variation exists in ratings by diagnosis and age.